Successful treatment of genital ulcers with infliximab in Behcet's disease.

Combination therapy of infliximab and thalidomide for refractory entero-Behcet's disease: a case report

BACKGROUND Behcet's disease (BD) is a systemic inflammatory disease with the histopathological features of leukocytoclastic vasculitis that affects nearly all organs and systems. When it involves the intestine, it is called entero-Behcet's disease (entero-BD). CASE PRESENTATION Here we described a 23-year-old man with entero-BD refractory to conventional therapies who responded well to the co...

Frequency of ocular involvement in 100 cases of Behcet syndrome in Babol, North of Iran

Background: Behcet syndrome is a recurrent inflammatory disorder that frequently involves the ocular system. The purpose of this study was to determine the frequency of ocular involvement in cases of Behcet's disease in Babol, north of Iran. Methods: From April 2003 to December 2009, 100 cases of behcet's disease who were admitted at the Department of Ophthalmology and Internal Medicine of Babo...

Isolated cutaneous Crohn’s disease: A case report

This case report describes a patient with cutaneous signs in the genital and peri-anal region suspicious of Crohn’s disease without any intestinal symptom or sign. Inflammatory bowel disease can be associated with some cutaneous signs. However, in this paper, we report a patient with isolated cutaneous Crohn’s disease which is very rare (less than 100 case reports across the world). Our patient...

ASSOCIATION STUDY OF MIR-146A RS2910164 AND RS57095329 POLYMORPHISMS WITH RISK OF BEHCET’S DISEASE

Background & Aims: Behcet's disease (BD) is an autoimmune disease that usually occurs with oral, genital and ocular ulcers. The cause of this disease is unknown and environmental, genetic and immunological factors contribute to its development. In the present study, the relation between rs2910164 and rs57095329 polymorphisms of miR146a gene with the potential for BD was investigated in Iranian ...

Successful Treatment of Refractory Behçet's Disease with the TNF-α Blocker Infliximab